Next Article in Journal
Guideline-Directed Medical Therapy in Sepsis Survivors with Left Ventricular Systolic Dysfunction: An Observational Study
Previous Article in Journal
The Role of Periarticular Knee Muscle Torques in Ensuring the Body Balance of Older Adults with Balance Disturbances
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 14
Issue 9
10.3390/jcm14093252
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Demographic and Socio-Economic Disparities in the Outcomes Among Patients with NVAF Treated with Oral Anticoagulants: A Real-World Evaluation of Medicare Beneficiaries

by
Nipun Atreja
1,†,
Anandkumar Dubey
1,*,
Monal Kohli
2,
Jenny Jiang
1,
Melissa Hagan
1,†,
Gideon Aweh
2,
Shayna Adams
2 and
Dong Cheng
1
1
Bristol Myers Squibb, Lawrenceville, NJ 08648, USA
2
STATinMED LLC, Dallas, TX 75240, USA
*
Author to whom correspondence should be addressed.
†
Nipun Atreja and Melissa Hagan are no longer employees of Bristol Myers Squibb. They participated in the study when they were employees of Bristol Myers Squibb.
J. Clin. Med. 2025, 14(9), 3252; https://doi.org/10.3390/jcm14093252
Submission received: 27 March 2025 / Revised: 23 April 2025 / Accepted: 29 April 2025 / Published: 7 May 2025
(This article belongs to the Section Cardiovascular Medicine)
Browse Figures
Versions Notes

Abstract

:
Objectives: To assess the association between apixaban use and the risk of stroke/systemic embolism (SE) and major bleeding (MB) compared with other anticoagulants (OACs) across demographic and socio-economic subgroups in the treatment of nonvalvular atrial fibrillation (NVAF). Methods: The study included adult NVAF patients initiating OAC treatment between 2013 and 2019 in the Medicare database. Inverse probability treatment weighted Cox proportional hazard models were used to assess stroke/SE and MB outcomes across various subgroups. Results: Overall, the adjusted risks of stroke/SE and MB were lower for apixaban compared with warfarin (stroke/SE: HR, 0.69, [95% confidence interval (CI): 0.65–0.74], MB: 0.59 [95% CI: 0.57–0.60]), rivaroxaban (stroke/SE: 0.88 [95% CI: 0.84–0.92], MB: 0.60 [95% CI: 0.58–0.61]) and dabigatran (stroke/SE: 0.88 [95% CI: 0.80–0.95], MB: 0.76 [95% CI: 0.72–0.80]). Among the low socio-economic status (SES) group, apixaban was associated with lower risk vs. warfarin (stroke/SE: 0.73 [95% CI: 0.69–0.77], MB: 0.60 [95% CI: 0.57–0.62]) and rivaroxaban (stroke/SE: 0.88 [95% CI: 0.83–0.94], MB: 0.61 [95% CI: 0.59–0.63]). Among medium SES patients, apixaban was associated with lower risk vs. warfarin (stroke/SE: 0.67 [95% CI: 0.63–0.71] MB: 0.60 [95% CI: 0.58–0.63]), rivaroxaban (stroke/SE: 0.85 [95% CI: 0.79–0.91], MB: 0.59 [95% CI: 0.56–0.61]) and dabigatran (stroke/SE: 0.85 [95% CI: 0.73–0.99], MB: 0.77 [95% CI: 0.70–0.84]). Apixaban was also associated with lower risks of stroke/SE and MB compared with other OACs among most other demographic, socio-economic subgroups. Conclusions: Apixaban was associated with lower risk of stroke/SE and MB than warfarin, rivaroxaban, dabigatran across most demographic, socio-economic subgroups.

1. Introduction

Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice, with an estimated worldwide prevalence of 59.7 million in 2019 [1]. In the United States (US), both the incidence and prevalence of AF are projected to increase, with the prevalence of AF estimated to be 12 million by 2030 [2]. AF is associated with an increased risk of thromboembolic events such as stroke and systemic embolism (SE) [3,4,5]. AF-related strokes have worse outcomes when compared to strokes due to other causes [6]. Additionally, AF is associated with significantly higher mean total healthcare costs per patient per year than for patients without AF (>$27,000 higher, p < 0.001) [7]. Nonvalvular atrial fibrillation (NVAF), defined as AF in the absence of moderate-to-severe mitral stenosis or a mechanical heart valve, is the most prevalent type of AF. In 2018, there were 6.4–7.4 million NVAF diagnoses [8].
Warfarin, a vitamin K antagonist (VKA), has been used for decades for reducing the stroke risk in AF patients [8,9]. It was shown that warfarin users had a 62% reduced risk of stroke than the control arms, including either placebo, aspirin, or other antithrombotic regimens used in clinical practice before 1999 [10]. However, the optimal results of warfarin treatment depend on the maintenance of an international normalized ratio (INR) within a narrow therapeutic range that requires frequent monitoring [11,12]. Failure to maintain the optimal INR may lead to a higher risk of admission to hospital or death due to hemorrhagic or ischemic events [12,13,14,15]. Consequently, patients with poor INR control are also more likely to discontinue warfarin within a year [16,17].
Direct-acting oral anticoagulants (DOACs) are a group of new oral anticoagulants, including direct oral factor Xa inhibitors and direct thrombin inhibitors [8]. Over the past decade, multiple randomized clinical trials have been conducted to compare DOACs with warfarin, demonstrating a favorable efficacy and safety profile for DOACs [18,19,20,21,22]. As a result, DOACs—including apixaban, rivaroxaban, dabigatran, and edoxaban have been approved in the US to reduce the risk of stroke in NVAF patients. Since their approval, several observational studies have also shown that DOAC users were associated with similar or lower risks of stroke/SE and major bleeding compared to warfarin in real-world settings [23,24,25,26,27,28,29]. In addition, DOACs were also associated with lower or comparable healthcare expenditure and/or healthcare utilization than warfarin in other real-world settings [30].
No head-to-head randomized control trials have been published that compare the efficacy and safety profiles among DOACs. However, several retrospective real-world data studies showed that apixaban was associated with a lower risk of stroke/SE and MB compared to rivaroxaban and dabigatran [27,28,31,32].
Patients in the older age group have a higher burden of not only AF but also a higher risk of hemorrhagic complications [33]. Moreover, women with AF have also shown higher rates of stroke than men [34]. These high-risk demographic groups are underrepresented in the medical literature comparing the effectiveness and safety profiles of DOACs with warfarin. Despite the steady increase in DOAC use since their approval and recommendation over warfarin as the first-line therapy for the treatment of NVAF [8,9], there remain disparities in DOAC use across different demographic and socio-economic groups. It was shown that DOAC use was lower among Black, women, and patients with low household incomes [35,36]. Individuals from underrepresented racial and ethnic groups with AF have higher rates of stroke and mortality relative to White patients [37,38]. Furthermore, there is no report comparing the effectiveness and safety outcomes of OACs among various demographic and socio-economic subgroups to date.
The current real-world study was conducted to fill the evidence gap by assessing the associations of the risk of stroke/SE and MB with OAC use across the different demographic and socio-economic subgroups in the Medicare population.

2. Methods

2.1. Data Source

This retrospective observational study utilized research-identifiable fee-for-service (FFS) Medicare claims data from the US Centers for Medicare and Medicaid Services (CMS). CMS Medicare is the federal health insurance program that comprises ~38 million FFS beneficiaries for people aged ≥65 years, certain younger people with disabilities, and people with end-stage renal disease. The database contains medical and pharmacy claims from 100% national Medicare data, which includes hospital inpatient, outpatient, physician visits, Part D, skilled nursing facility, home health agency, and durable medical equipment claims. All the methods in the current study were carried out per the Declaration of Helsinki. This study used a secondary de-identified database in compliance with the US privacy laws and regulations, i.e., the Health Insurance Portability and Accountability Act (HIPAA) of 1996. This study did not involve interaction with human subjects; the collection, use, or transmittal of individually identifiable data; and does not fall under the regulatory definitions of human subjects research; thus, is exempt from the institutional review board (IRB) review and the requirement to obtain written informed consent from participants, as defined by the US Department of Health and Human Services regulations—45 CFR 46.102(f)(2).

2.2. Study Design and Population

The study period was between 1 January 2012, and 31 December 2019, including a 12-month baseline period. Patients were included in this study if they had ≥1 inpatient claim or ≥2 outpatient claims for AF (at least 7 days gap between the 2 outpatient claims), identified using International Classification of Diseases, Ninth/Tenth Revision, Clinical Modification (ICD-9-CM/ICD-10-CM) diagnosis codes (see Table S1, Supplementary Materials). The first AF diagnosis claim date should lie between 1 January 2013, and 31 December 2019. Patients were required to have a prescription for an OAC in this period, on or after the first AF diagnosis, and had 12 months of continuous health plan enrollment with medical and pharmacy benefits before treatment initiation.
Patients were excluded if they had medical claims indicating a chronic condition, like diagnosis of rheumatic mitral valvular heart disease, venous thromboembolism, transient AF (related to heart valve replacement/transplant, pericarditis, hyperthyroidism, and thyrotoxicity) within the 12 months before or on the index date. Additionally, patients with evidence of pregnancy during the study period were excluded. Other exclusion criteria included recent events such as medical claims indicating hip/knee replacement surgery within six weeks before the index date, pharmacy claims for specific anticoagulants (warfarin, apixaban, rivaroxaban, dabigatran or edoxaban) during the baseline period, and having more than one type of OAC prescription claim on the index date. The index date was defined as the first prescription date of an OAC during the identification period, and the baseline period was defined as 12 months prior to the index date. The follow-up period started from the day after the index date until 30 days after discontinuation of the index OAC, switch to another OAC, death, end of the study period, or health plan disenrollment, whichever occurred earliest. Patients were considered discontinued if there was no extra refill for the index OAC after 30 days of the previous prescription’s run-out date. The discontinuation date was defined as the prescription run-out date. A switch among index OACs was defined as a prescription filled for non-index OAC within 30 days before or after the run-out date. Patients with zero days of follow-up were excluded. Figure 1 denotes a graphical representation of the study design.

2.3. Exposure, Outcome, and Covariate Identification

Patients were categorized into four cohorts based on their index prescription of warfarin, apixaban, rivaroxaban, or dabigatran. Due to the low use of edoxaban, it was not further analyzed by this study. The primary outcome events were stroke/SE or MB, identified using ICD-9/10-CM codes in the follow-up period. A stroke/SE event was stratified into three categories: ischemic stroke, hemorrhage stroke, and SE (see Table S2, Supplementary Materials). An MB event was stratified into three categories: gastrointestinal hemorrhage, intracranial hemorrhage, and other bleeding (see Table S3, Supplementary Materials). The time to event was assessed and defined as the number of days from the index date to the first stroke/SE or MB occurrence. The stroke/SE or MB incidence rate was calculated per 100 person-years.
Covariates measured in the baseline period included age, gender, race, geographic region, Medicare/Medicaid dual eligibility, Part D low-income subsidy (LIS), and socio-economic status (SES). Age was classified into 65–74, 75–84, and 85+ years old groups. Race was categorized into White, Black, Asian, and other categories. Geographic regions included Northeast, Midwest, South, West, and Unknown. Medicare/Medicaid dual eligibility was used as a binary variable depending on status in index month and year. Part D low-income subsidy was also a binary variable, and patients were considered for LIS if they received any percentage of Part D subsidy on the index date. SES included low SES if it was within 0–200% of the federal poverty level (FPL), medium SES within 201–400%, and high SES if it was 401% or greater. In addition, baseline clinical variables included the Deyo–Charlson comorbidity index (CCI) score, CHA2DS2-VASc score, HAS-BLED score, history of bleeding, history of stroke/SE, obesity, congestive heart failure, diabetes mellitus, hypertension, chronic obstructive pulmonary disease (COPD), renal disease, myocardial infarction, dyspepsia or stomach discomfort, non-stroke/SE peripheral vascular disease, transient ischemic attack (TIA), coronary artery disease (CAD), baseline medication use such as angiotensin-converting enzyme inhibitors, amiodarone, angiotensin receptor blockers, beta-blockers, H2-receptor antagonists, proton pump inhibitors, anti-platelets, statins, and nonsteroidal anti-inflammatory drugs (NSAIDs). Index DOAC dose which was categorized as standard (apixaban: 5 mg; rivaroxaban: 20 mg; dabigatran: 150 mg), or low dose (apixaban: 2.5 mg; rivaroxaban: 15 mg; dabigatran: 75 mg, 110 mg). All warfarin doses were categorized as standard.

2.4. Statistical Analysis

Baseline demographic and clinical characteristics were summarized using means, medians, and standard deviations for continuous variables, and categorical variables were described with frequency counts and percentages. Continuous variables were compared using a t-test, whereas categorical variables were compared using a chi-square test between cohorts.
Inverse probability treatment weighting (IPTW) was used to balance patient characteristics and remove confounders when comparing outcomes. IPTW used propensity scores to estimate a treatment’s average effect in the OAC treatment cohorts, conditional on the following observed baseline covariates: age, gender, race, dual eligibility, LIS, SES, index year, baseline comorbidities, and medication use. The propensity score was calculated using a multinomial logistic regression with warfarin users as a reference group. Cox proportional hazard models were used to assess the association of OACs with stroke/SE and MB events. The hazard ratio and 95% confidence intervals (CI) are provided. Statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC, USA).
Subgroup analyses were conducted to determine whether the associations of OAC treatment with stroke/SE and MB events differ by demographic or socio-economic groups, with a specific focus on SES.

3. Results

A total of 5,344,412 patients who had claims for any of the OACs of interest during the identification period were identified. After applying the inclusion and exclusion criteria, 1,079,540 eligible patients were included in the final analyses (Figure 2).

3.1. Study Cohorts and Baseline Characteristics

There were 278,372 patients in the warfarin cohort, 486,257 in the apixaban cohort, 267,991 in the rivaroxaban cohort, and 46,920 in the dabigatran cohort. The edoxaban cohort was not included in the analysis because of the low sample size (N = 1137). Baseline patient characteristics before and after IPTW are presented in Table 1 and Table 2, respectively.
Homogeneity of patient characteristics across cohorts after IPTW (Table 2) was demonstrated by the standardized difference (STD) values of less than 10% [39]. Most patients in all the weighted cohorts were at least 77 years old, with 78.3–79.2% in the age range 65–84 years, White (88.1–89.5%), and residing in the Southern (37.5–39.3%) or Midwest (23.6–26.3%) region of US at baseline. There was almost an equal proportion of male (47.8–51.4%) to female (48.6–52.2%) patients in all treatment arms. However, patients in the warfarin cohort were more likely to be male (51.4%) and have medium SES (40.9%) compared to all other cohorts. Patients in the rivaroxaban cohort were more likely to receive Part D low-income subsidy (20.6%) and be dual Medicaid eligible (15.4%) than all other cohorts. There were 13.2–15.4% patients with dual Medicaid eligibility and 18.1–20.6% patients with Part D low-income subsidy.
The utilization trend of OACs was similar in all treatment arms between the 2013 and 2019 index years. OAC use increased from 11.7–11.8% in 2013 to 16.0–16.2% in 2018, and then a minor decrease in 2019 (15.5–15.7%). The mean Deyo–Charlson comorbidity index score, CHA2DS2-VASc score, and HAS-BLED scores were lowest in the apixaban (5.4, 4.5, 2.6) cohort compared to the other cohorts. The mean Deyo–Charlson comorbidity index score was highest in the warfarin (5.5) cohort. The mean CHA2DS2-VASc and HAS-BLED scores were highest in dabigatran (4.5, 2.6). The most common comorbidities at baseline in all cohorts were hypertension (83.1–85.6%), CAD (41.38–42.7%), and diabetes mellitus (34.5–36.2%). Around 12.0–14.4% had a history of stroke, and 16.7–19.3% had a history of bleeding. The most common medications at baseline in all cohorts were statins (55.2–58.8%) and beta blockers (59.2–63.4%). Most patients in the DOAC cohorts received a standard dose (62.4–73.9%).
The average follow-up time ranged from 335 (dabigatran) to 455 (apixaban) days. Dabigatran patients were least likely to be censored due to death, disenrollment, end of study period, or discontinuation. This was likely because they were the most likely to switch (19.7%) compared to all other cohorts. Switch rates were lower in the apixaban cohort (6.4%) compared to the warfarin (13.8%), dabigatran (19.7%), and rivaroxaban (10.2%) cohorts. Dabigatran patients had the lowest proportion of incident stroke (1.2%), followed by apixaban and rivaroxaban (both approximately 1.3%). Apixaban had the longest time to stroke (376 days) compared to other cohorts. Apixaban had the lowest incidence rate of both stroke/SE (1.1 per 100 person-years) and MB (2.3 per 100 person-years) compared to the other cohorts.

3.2. Outcomes

Among the overall cohort, patients on apixaban had a 31% lower risk of stroke (HR: 0.69 [95% confidence interval (CI): 0.65–0.74]; p < 0.0001) and 41% lower risk of MB (HR: 0.59 [95% CI: 0.57–0.60]; p < 0.0001) than warfarin (Table 3 and Table 4). Patients on dabigatran had a 28% lower risk of stroke (HR: 0.82 [95% CI: 0.69–0.98]; p = 0.0254) and 23% lower risk of MB (HR: 0.77 [95% CI: 0.73–0.81]; p < 0.0001) than warfarin. Patients on rivaroxaban had a 23% lower risk of stroke (HR: 0.77 [95% CI: 0.71–0.84]; p < 0.0001) and a similar risk of MB (HR: 0.99 [95% CI: 0.96–1.01]; p = 0.3181) compared to warfarin. Patients on apixaban had a 12% lower risk of stroke (HR: 0.88 [95% CI: 0.84–0.92]; p < 0.0001) and 40% lower risk of MB (HR: 0.60 [95% CI: 0.58–0.61]; p < 0.0001) than rivaroxaban. Patients on apixaban also had a 12% lower risk of stroke (HR: 0.88 [95% CI: 0.80–0.95]; p = 0.0029) and 24% lower risk of MB (HR: 0.76 [95% CI: 0.72–0.80]; p < 0.0001) than dabigatran.
When stratified into various demographic subgroups, among females, a 28% lower risk for stroke/SE (HR: 0.73 [95% CI: 0.67–0.78]; p < 0.0001) and 40% lower risk for MB (HR: 0.60 [95% CI: 0.58–0.62]; p < 0.0001) was observed for apixaban, compared with warfarin. In comparison to rivaroxaban, apixaban was associated with a 12% lower risk of stroke/SE (HR: 0.88 [95% CI: 0.83–0.93]; p < 0.0001) and 41% lower risk of MB (HR: 0.59 [95% CI: 0.57–0.61]; p < 0.0001). Apixaban was associated with a similar risk of stroke/SE (HR: 0.98 [95% CI: 0.86–1.11]; p = 0.7383) and a 28% lower risk of MB (HR: 0.72 [95% CI: 0.66–0.77]; p < 0.0001) compared to dabigatran. Among males, the risks of stroke/SE and MB were significantly lower for apixaban compared with warfarin (p < 0.0001 for stroke/SE and MB), rivaroxaban (p = 0.003 for stroke/SE and p < 0.0001 for MB), and dabigatran (p = 0.0003 for stroke/SE and p < 0.0001 for MB; Table 3 and Table 4).
Among Black patients, the risk was lower for apixaban compared with warfarin (stroke/SE: 0.72 [95% CI: 0.63–0.83] p < 0.0001, and MB: 0.59 [95% CI: 0.54–0.65] p < 0.0001), also lower risk of MB for apixaban compared with rivaroxaban (MB: 0.56 [95% CI: 0.5–0.62] p < 0.0001), but similar risk of stroke/SE compared to rivaroxaban (p = 0.2314) and dabigatran (p = 0.105), and similar risk of MB compared to dabigatran (p = 0.3120). Among White patients, the risk of stroke/SE and MB was significantly lower for apixaban compared with warfarin (both p < 0.0001), rivaroxaban (both p < 0.0001), and dabigatran (SE p = 0.0007, MB p < 0.0001; detailed results in Table 3 and Table 4, respectively).
When stratified into various socio-economic subgroups, within the low SES patient subgroup, apixaban was associated with 27% lower risk of stroke (HR: 0.73 [95% CI: 0.69–0.77]; p < 0.0001) and 40% lower risk of MB (HR: 0.60 [95% CI: 0.57–0.62]; p < 0.0001) than warfarin. Apixaban was associated with a 12% lower risk of stroke (HR: 0.88 [95% CI: 0.83–0.94]; p = 0.0001) and 39% lower risk of MB (HR: 0.61 [95% CI: 0.59–0.63]; p < 0.0001) than rivaroxaban and a 24% lower risk of MB (HR: 0.76 [95% CI: 0.70–0.83]; p < 0.0001) than dabigatran.
Within medium SES patients, apixaban was associated with 33% lower risk of stroke (HR: 0.67 [95% CI: 0.63–0.71]; p < 0.0001) and 40% lower risk of MB (HR: 0.60 [95% CI: 0.58–0.63]; p < 0.0001) than warfarin. Apixaban was associated with 15% lower risk of stroke (HR: 0.85 [95% CI: 0.79–0.91]; p < 0.0001) and a 41% lower risk of MB (HR: 0.59 [95% CI: 0.56–0.61]; p < 0.0001) compared to rivaroxaban; and a 15% lower risk of stroke (HR: 0.85 [95% CI: 0.73–0.98]; p = 0.0231) and 23% lower risk of MB (HR: 0.77 [95% CI: 0.70–0.84]; p < 0.0001) than dabigatran.
Within high SES patients, apixaban was associated with 32% lower risk of stroke (HR: 0.68 [95% CI: 0.62–0.74]; p < 0.0001) and 44% lower risk of MB (HR: 0.56 [95% CI: 0.52–0.59]; p < 0.0001) than warfarin. Apixaban was associated with a 27% lower risk of stroke (HR: 0.73 [95% CI: 0.61–0.87]; p = 0.0006) and a 25% lower risk of MB (HR: 0.75 [95% CI: 0.66–0.85]; p < 0.0001) compared to dabigatran. Apixaban was associated with a 41% lower risk of MB (HR: 0.59 [95% CI: 0.55–0.62]; p < 0.0001) than rivaroxaban.

4. Discussion

The current study used real-world data to assess the risk of stroke/SE and MB associated with OACs within various demographic and socio-economic subgroups in the Medicare population. In particular, this study included previously underexplored patient populations, such as female, Black populations and patients of lower incomes defined by SES status and Medicare/Medicaid dual eligibility. Apixaban was associated with lower rates of stroke/SE and MB compared to other OACs across most strata and vulnerable patient populations. The final cohort included over one million patients. Most were White, residing in the Southern or Midwest region of the US, and about 40% belonged to underserved populations, denoted by the low SES group.
During the study period, utilization of apixaban steadily increased, rivaroxaban usage was relatively stable, and an overall decreasing trend was observed for warfarin and dabigatran. Less frequent laboratory monitoring, a more predictable pharmacokinetic (dosing) profile, fewer interactions with other drugs, and the non-inferior effectiveness and safety profile of DOACs may explain the increasing DOAC adoption trend in recent years [40,41].
All DOACs were associated with a lower risk of stroke/SE and MB compared to warfarin, except for rivaroxaban, which had a similar risk of MB compared to warfarin. This finding is consistent with a prior Bayesian network meta-analysis that summarized results from 53 real-world studies. Based on that meta-analysis, the use of apixaban, dabigatran, and edoxaban, but not rivaroxaban, was associated with a reduced risk of MB [42].
In the current study, apixaban use was associated with a lower risk of stroke/SE and MB compared to rivaroxaban, dabigatran, and warfarin in the overall study cohort. This result further confirmed a pivotal randomized clinical trial on apixaban [18], similar to the ARISTOPHANES study, wherein apixaban use was associated with about 40% lower risk of stroke/SE and MB than warfarin [27]. Ray et al. also noted that apixaban users had a lower risk of the composite of stroke/SE and MB compared to rivaroxaban [31], and the results from the current study echoed those earlier findings.
While DOACs are effective in reducing the risk of both stroke/SE and MB, there were differences in DOAC use between the different sociodemographic and socio-economic groups. Prior studies found that patients of Black race, women, the elderly, and with low household income were associated with low use of DOACs [35,36,43,44]. Furthermore, patients from underrepresented racial and ethnic groups with AF had higher rates of stroke and mortality [38,40]. These disparities may have profound implications for patients, particularly those from racial and ethnic minorities, women, and the underserved patient population [35,36,37,38,45]. Our study observed that apixaban was associated with a 20–40% lower risk of stroke/SE compared to warfarin across all subgroups. When compared with dabigatran, apixaban was also associated with a lower risk of stroke/SE among males, White patients, patients with medium and high SES, and those who were not Medicare/Medicaid dual eligible. In the remaining subgroups, apixaban use was as effective as dabigatran against stroke/SE. In comparison to rivaroxaban, apixaban also had a lower risk for stroke/SE among the majority subgroups and similar effectiveness among Black and Other race patients, those with high SES levels, and patients with Medicare/Medicaid dual eligibility.
For the MB safety outcome, apixaban was associated with a 40–50% lower risk compared to warfarin across all subgroups. Compared to dabigatran and rivaroxaban, apixaban was also associated with a lower risk of MB across most of the subgroups except in the 65–74 age group, racial subgroups other than White patients, and among the high SES group, where apixaban had a similar risk of MB as with dabigatran and rivaroxaban. The results for apixaban vs. warfarin among the overall study sample, age and gender subgroups were similar to the ARISTOPHANES study [27]. However, the remaining socio-economic subgroups in our study were not assessed in the ARISTOPHANES study.
Taken together, our study found differences in stroke/SE and MB risks depending on the OAC used, and those differences persisted across different age groups, genders, races, SES categories, and Medicare/Medicaid dual eligibility categories. Specifically, in the underserved patient population, denoted by the low SES group, apixaban showed a significantly lower risk of MB as compared to warfarin, rivaroxaban, and dabigatran and a significantly lower risk of stroke/SE compared to warfarin and rivaroxaban. These consistent results obtained from the large healthcare administrative databases help to strengthen the value of apixaban and its benefits across the demographic and socio-economic subgroups.
The current study has several strengths. First, the US CMS Medicare is a federal health insurance program for people aged ≥65 years. Therefore, the results may have greater generalizability among the US population aged 65 years or above. Second, the sample size is over one million, allowing us to conduct multiple subgroup analyses with a relatively large sample size within each subgroup. Third, a robust statistical methodology was used to account for confounding and included a large number of potential covariates in the model to reduce the possibility of residual confounding. However, the results should be interpreted in the context of the following potential limitations. First, due to the observational nature of this study, residual confounding is possible. However, IPTW was used to minimize the effect of residual confounding—by balancing patient characteristics and removing confounders when comparing outcomes. Second, exposure was defined based on pharmacy fills, and filling a prescription does not necessarily mean the medication was consumed, and this could have resulted in exposure misclassification. However, this misclassification is possible across all cohorts and is likely non-differential. Therefore, the results were likely conservative. Third, study outcomes were identified using ICD, CPT, and HCPCS codes and therefore, it is possible to have outcome misclassification due to coding error or data entry errors. Again, this misclassification is also likely a non-differential misclassification. Fourth, SES status was based upon the FPL cut-off on median household income and may have misclassified some patients as this was a proxy variable. Fifth, it should also be noted that unobserved heterogeneity may exist across the datasets used in this analysis. However, the likelihood of duplicate observations is low, researched to be 0.5%, and not likely to significantly impact study results. Sixth, while competing risks, such as treatment switching, were present, we did not employ competing risk analyses, which may overestimate event rates in groups with higher switching. However, given the low overall switching rates (pre-IPTW 9.3%; post-IPTW 9.8%), we anticipate minimal impact on between-group risk comparisons. Finally, edoxaban was excluded due to low sample size during the study period, though its increasing use in recent years warrants future investigation. Additionally, dose-specific effects could not be assessed due to sample size constraints; future studies should explore this.

5. Conclusions

The current study found that in the Medicare population, apixaban was associated with lower risks of stroke/SE and MB when compared to warfarin, rivaroxaban, and dabigatran. Importantly, apixaban use was associated with a 20–40% lower risk of stroke/SE and a 40–50% lower MB risk compared to warfarin across most demographic and socio-economic subgroups. These results highlight the effectiveness of apixaban in reducing the risk of stroke/SE with reduced major bleeding risk across diverse demographic and socio-economic groups in real-world settings, especially among female and Black populations and those in low SES groups.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm14093252/s1, Figure S1: Comparison between apixaban vs. warfarin on the risk of stroke/SE among the overall population and by demographic and socioeconomic status subgroups; Figure S2: Comparison between apixaban vs. warfarin on the risk of major bleeding among the overall population and by demographic and socioeconomic status subgroups; Figure S3: Comparison between apixaban vs. rivaroxaban on the risk of stroke/se among the overall population and by demographic and socioeconomic status subgroups; Figure S4: Comparison between apixaban vs. rivaroxaban on the risk of major bleeding among the overall population and by demographic and socioeconomic status subgroups; Figure S5: Comparison between apixaban vs. dabigatran on the risk of stroke/se among the overall population and by demographic and socioeconomic status subgroups; Figure S6: Comparison between apixaban vs. dabigatran on the risk of major bleeding among the overall population and by demographic and socioeconomic status subgroups; Figure S7: Comparison between dabigatran vs. rivaroxaban on the risk of stroke/se among the overall population and by demographic and socioeconomic status subgroups; Figure S8: Comparison between dabigatran vs. rivaroxaban on the risk of major bleeding among the overall population and by demographic and socioeconomic status subgroups; Figure S9: Comparison between rivaroxaban vs. warfarin on the risk of stroke/se among the overall population and by demographic and socioeconomic status subgroups; Figure S10: Comparison between rivaroxaban vs. warfarin on the risk of major bleeding among the overall population and by demographic and socioeconomic status subgroups; Figure S11: Comparison between dabigatran vs. warfarin on the risk of stroke/se among the overall population and by demographic and socioeconomic status subgroups; Figure S12: Comparison between dabigatran vs. warfarin on the risk of major bleeding among the overall population and by demographic and socioeconomic status subgroups; Table S1: ICD codes for atrial fibrillation; Table S2: ICD codes for stroke event; Table S3: ICD codes for bleeding events.

Author Contributions

Concept and design, N.A., M.K., J.J., M.H., G.A., S.A. and D.C.; acquisition of data: N.A., M.K., G.A., S.A. and D.C.; analysis and interpretation of data: N.A., M.K., J.J., M.H., G.A., S.A., D.C. and A.D.; drafting of the manuscript: N.A., M.K., J.J., M.H., G.A., S.A. and D.C.; critical revision of the paper for important intellectual content: N.A., M.K., J.J., M.H., G.A., S.A., D.C. and A.D.; obtaining funding: N.A.; administrative, technical, or logistic support: N.A., M.K., J.J., M.H., G.A., S.A., D.C. and A.D.; supervision: N.A. and A.D. All authors have read and agreed to the published version of the manuscript.

Funding

This work was funded by Bristol Myers Squibb (BMS) and Pfizer. Medical writing support was provided by Complete HEOR Solutions (CHEORS) (Chalfont, USA) and was funded by BMS and Pfizer.

Institutional Review Board Statement

This study did not involve the interaction with human subjects, collection, use, or transmittal of individually identifiable data, and does not fall under the regulatory definitions of human subjects research; thus, is exempt from the institutional review board, as defined by the US Department of Health and Human Services regulations—45 CFR 46.102(f)(2).

Informed Consent Statement

Not applicable.

Data Availability Statement

Restrictions apply to the availability of these data. The datasets generated and/or analyzed for the current study are not publicly available due to the confidential and proprietary nature of the datasets.

Conflicts of Interest

A.D., J.J. and D.C. are employees of BMS and may hold BMS stocks. M.K. and G.A. are employees of STATinMED. N.A. and M.H. were employees of BMS and S.A. was an employee of STATinMED at the time that the study was conducted. The sponsor was involved in the conception and design, analysis and interpretation of the data, drafting of the paper and revising it critically for intellectual content.

Abbreviations

The following abbreviations are used in this manuscript:
ACEangiotensin-converting enzyme
AFatrial fibrillation
ARBangiotensin receptor blocker
CADcoronary artery disease
CCIDeyo–Charlson comorbidity index
CHFcongestive heart failure
CIconfidence interval
CMSUS Centers for Medicare and Medicaid Services
COPDchronic obstructive pulmonary disease
DMdiabetes mellitus
FFSfee-for-service
FPLfederal poverty level
DOACdirect-acting oral anticoagulants
HIPAAHealth Insurance Portability and Accountability Act
HRhazard ratio
ICD-9-CMInternational Classification of Diseases, Ninth Revision, Clinical Modification
ICD-10-CMInternational Classification of Diseases, Tenth Revision, Clinical Modification
INRinternational normalized ratio
IPTWinverse probability treatment weighting
IRBinstitutional review board
LISlow-income subsidy
MBmajor bleeding
MImyocardial infarction
NSAIDnonsteroidal anti-inflammatory drugs
NVAFnonvalvular atrial fibrillation
OACoral anticoagulant
PADperipheral arterial disease
PVDperipheral vascular disease
RAreceptor antagonist
SDstandard deviation
SEsystemic embolism
SESsocio-economic status
STDstandardized mean difference
TIAtransient ischemic attack
USUnited States
VKAvitamin K antagonist

References

  1. Roth, G.A.; Mensah, G.A.; Johnson, C.O.; Addolorato, G.; Ammirati, E.; Baddour, L.M.; Barengo, N.C.; Beaton, A.Z.; Benjamin, E.J.; Benziger, C.P.; et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update from the GBD 2019 Study. J. Am. Coll. Cardiol. 2020, 76, 2982–3021. [Google Scholar] [CrossRef] [PubMed]
  2. Colilla, S.; Crow, A.; Petkun, W.; Singer, D.E.; Simon, T.; Liu, X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am. J. Cardiol. 2013, 112, 1142–1147. [Google Scholar] [CrossRef] [PubMed]
  3. Virani, S.S.; Alonso, A.; Aparicio, H.J.; Benjamin, E.J.; Bittencourt, M.S.; Callaway, C.W.; Carson, A.P.; Chamberlain, A.M.; Cheng, S.; Delling, F.N.; et al. Heart Disease and Stroke Statistics-2021 Update: A Report from the American Heart Association. Circulation 2021, 143, e254–e743. [Google Scholar] [CrossRef] [PubMed]
  4. Ding, W.Y. Residual Stroke Risk in Atrial Fibrillation. Arrhythm. Electrophysiol. Rev. 2021, 10, 147–153. [Google Scholar] [CrossRef]
  5. Healey, J.S.; Connolly, S.J.; Gold, M.R.; Israel, C.W.; Van, G.I.; Capucci, A.; Lau, C.P.; Fain, E.; Yang, S.; Bailleul, C.; et al. Subclinical atrial fibrillation and the risk of stroke. N. Engl. J. Med. 2012, 366, 120–129. [Google Scholar] [CrossRef]
  6. Ali, A.N.; Abdelhafiz, A. Clinical and Economic Implications of AF Related Stroke. J. Atr. Fibrillation 2016, 8, 1279. [Google Scholar] [CrossRef]
  7. Deshmukh, A.; Iglesias, M.; Khanna, R.; Beaulieu, T. Healthcare utilization and costs associated with a diagnosis of incident atrial fibrillation. Heart Rhythm O2 2022, 3, 577–586. [Google Scholar] [CrossRef]
  8. January, C.T.; Wann, L.S.; Calkins, H.; Chen, L.Y.; Cigarroa, J.E.; Cleveland, J.C., Jr.; Ellinor, P.T.; Ezekowitz, M.D.; Field, M.E.; Furie, K.L.; et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration with the Society of Thoracic Surgeons. Circulation 2019, 140, e125–e151. [Google Scholar] [CrossRef]
  9. Joglar, J.A.; Chung, M.K.; Armbruster, A.L.; Benjamin, E.J.; Chyou, J.Y.; Cronin, E.M.; Deswal, A.; Eckhardt, L.L.; Goldberger, Z.D.; Gopinathannair, R.; et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 2024, 83, 109–279. [Google Scholar] [CrossRef]
  10. Hart, R.G.; Benavente, O.; McBride, R.; Pearce, L.A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann. Intern. Med. 1999, 131, 492–501. [Google Scholar] [CrossRef]
  11. Cannegieter, S.C.; Rosendaal, F.R.; Wintzen, A.R.; van der Meer, F.J.; Vandenbroucke, J.P.; Briët, E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N. Engl. J. Med. 1995, 333, 11–17. [Google Scholar] [CrossRef] [PubMed]
  12. Oden, A.; Fahlen, M.; Hart, R.G. Optimal INR for prevention of stroke and death in atrial fibrillation: A critical appraisal. Thromb. Res. 2006, 117, 493–499. [Google Scholar] [CrossRef] [PubMed]
  13. Hylek, E.M.; Go, A.S.; Chang, Y.; Jensvold, N.G.; Henault, L.E.; Selby, J.V.; Singer, D.E. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N. Engl. J. Med. 2003, 349, 1019–1026. [Google Scholar] [CrossRef] [PubMed]
  14. Spyropoulos, A.C. Managing oral anticoagulation requires expert experience and clinical evidence. J. Thromb. Thrombolysis 2006, 21, 91–94. [Google Scholar] [CrossRef]
  15. Ay, H.; Arsava, E.M.; Gungor, L.; Greer, D.; Singhal, A.B.; Furie, K.L.; Koroshetz, W.J.; Sorensen, A.G. Admission international normalized ratio and acute infarct volume in ischemic stroke. Ann. Neurol. 2008, 64, 499–506. [Google Scholar] [CrossRef]
  16. Birman-Deych, E.; Radford, M.J.; Nilasena, D.S.; Gage, B.F. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 2006, 37, 1070–1074. [Google Scholar] [CrossRef]
  17. Nelson, W.W.; Milentijevic, D.; Wang, L.; Baser, O.; Damaraju, C.V.; Schein, J.R. Patterns of international normalized ratio values among new warfarin patients with nonvalvular atrial fibrillation. Blood Coagul. Fibrinolysis 2016, 27, 899–906. [Google Scholar] [CrossRef]
  18. Granger, C.B.; Alexander, J.H.; McMurray, J.J.; Lopes, R.D.; Hylek, E.; Hanna, M.; Al-Khalidi, H.R.; Ansell, J.; Atar, D.; Avezum, A.; et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2011, 365, 981–992. [Google Scholar] [CrossRef]
  19. Patel, M.R.; Mahaffey, K.W.; Garg, J.; Pan, G.; Singer, D.E.; Hacke, W.; Breithardt, G.; Halperin, J.L.; Hankey, G.J.; Piccini, J.P.; et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011, 365, 883–891. [Google Scholar] [CrossRef]
  20. Alcalai, R.; Butnaru, A.; Moravsky, G.; Yagel, O.; Rashad, R.; Ibrahimli, M.; Planer, D.; Amir, O.; Elbaz-Greener, G.; Leibowitz, D. Apixaban vs. warfarin in patients with left ventricular thrombus: A prospective multicentre randomized clinical trial. Eur. Heart J. Cardiovasc. Pharmacother. 2022, 8, 660–667. [Google Scholar] [CrossRef]
  21. Connolly, S.J.; Ezekowitz, M.D.; Yusuf, S.; Eikelboom, J.; Oldgren, J.; Parekh, A.; Pogue, J.; Reilly, P.A.; Themeles, E.; Varrone, J.; et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009, 361, 1139–1151. [Google Scholar] [CrossRef] [PubMed]
  22. Giugliano, R.P.; Ruff, C.T.; Braunwald, E.; Murphy, S.A.; Wiviott, S.D.; Halperin, J.L.; Waldo, A.L.; Ezekowitz, M.D.; Weitz, J.I.; Spinar, J.; et al. Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2013, 369, 2093–2104. [Google Scholar] [CrossRef] [PubMed]
  23. Fawzy, A.M.; Yang, W.Y.; Lip, G.Y. Safety of direct oral anticoagulants in real-world clinical practice: Translating the trials to everyday clinical management. Expert. Opin. Drug Saf. 2019, 18, 187–209. [Google Scholar] [CrossRef] [PubMed]
  24. Miyazaki, S.; Miyauchi, K.; Hayashi, H.; Yamashiro, K.; Tanaka, R.; Nishizaki, Y.; Nojiri, S.; Suwa, S.; Sumiyoshi, M.; Nakazato, Y.; et al. Trends of anticoagulant use and outcomes of patients with non-valvular atrial fibrillation: Findings from the RAFFINE registry. J. Cardiol. 2022, 80, 41–48. [Google Scholar] [CrossRef]
  25. Chen, H.Y.; Ou, S.H.; Huang, C.W.; Lee, P.T.; Chou, K.J.; Lin, P.C.; Su, Y.C. Efficacy and Safety of Direct Oral Anticoagulants vs. Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis. Clin. Drug Investig. 2021, 41, 341–351. [Google Scholar] [CrossRef]
  26. Harrington, J.; Carnicelli, A.P.; Hua, K.; Wallentin, L.; Patel, M.R.; Hohnloser, S.H.; Giugliano, R.P.; Fox, K.A.A.; Hijazi, Z.; Lopes, R.D.; et al. Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses from COMBINE AF. Circulation 2023, 147, 1748–1757. [Google Scholar] [CrossRef]
  27. Lip, G.Y.H.; Keshishian, A.; Li, X.; Hamilton, M.; Masseria, C.; Gupta, K.; Luo, X.; Mardekian, J.; Friend, K.; Nadkarni, A.; et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke 2018, 49, 2933–2944. [Google Scholar] [CrossRef]
  28. Atreja, N.; Dubey, A.; Kang, A.; Jiang, J.; Hagan, M.; Michael-Asalu, A.; Cheng, D.; Deitelzweig, S. Effectiveness and Safety in Patients with Non-Valvular Atrial Fibrillation Who Switched from Warfarin to Direct Oral Anticoagulants in Medicare Population. Adv. Ther. 2025, 42, 1462–1483. [Google Scholar] [CrossRef]
  29. Deitelzweig, S.; Farmer, C.; Luo, X.; Vo, L.; Li, X.; Hamilton, M.; Horblyuk, R.; Ashaye, A. Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: A systematic review of real-world observational studies. Curr. Med. Res. Opin. 2017, 33, 1583–1594. [Google Scholar] [CrossRef]
  30. Hallinen, T.; Soini, E.; Asseburg, C.; Linna, M.; Eloranta, P.; Sintonen, S.; Kosunen, M. Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation. ClinicoEconomics Outcomes Res. 2021, 13, 745–755. [Google Scholar] [CrossRef]
  31. Ray, W.A.; Chung, C.P.; Stein, C.M.; Smalley, W.; Zimmerman, E.; Dupont, W.D.; Hung, A.M.; Daugherty, J.R.; Dickson, A.; Murray, K.T. Association of Rivaroxaban vs. Apixaban with Major Ischemic or Hemorrhagic Events in Patients with Atrial Fibrillation. JAMA 2021, 326, 2395–2404. [Google Scholar] [CrossRef] [PubMed]
  32. Deitelzweig, S.; Kang, A.; Jiang, J.; Gao, C.; Luo, X.; Atreja, N.; Han, S.; Cheng, D.; Loganathan, S.R.; Lip, G.Y.H. Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation. J. Clin. Med. 2024, 13, 1073. [Google Scholar] [CrossRef] [PubMed]
  33. Wasmer, K.; Eckardt, L.; Breithardt, G. Predisposing factors for atrial fibrillation in the elderly. J. Geriatr. Cardiol. 2017, 14, 179–184. [Google Scholar] [CrossRef]
  34. Shroff, G.R.; Solid, C.A.; Herzog, C.A. Atrial fibrillation, stroke, and anticoagulation in Medicare beneficiaries: Trends by age, sex, and race, 1992–2010. J. Am. Heart Assoc. 2014, 3, e000756. [Google Scholar] [CrossRef]
  35. Essien, U.R.; Magnani, J.W.; Chen, N.; Gellad, W.F.; Fine, M.J.; Hernandez, I. Race/Ethnicity and Sex-Related Differences in Direct Oral Anticoagulant Initiation in Newly Diagnosed Atrial Fibrillation: A Retrospective Study of Medicare Data. J. Natl. Med. Assoc. 2020, 112, 103–108. [Google Scholar] [CrossRef]
  36. Nathan, A.S.; Geng, Z.; Dayoub, E.J.; Khatana, S.A.M.; Eberly, L.A.; Kobayashi, T.; Pugliese, S.C.; Adusumalli, S.; Giri, J.; Groeneveld, P.W. Racial, Ethnic, and Socioeconomic Inequities in the Prescription of Direct Oral Anticoagulants in Patients with Venous Thromboembolism in the United States. Circ. Cardiovasc. Qual. Outcomes 2019, 12, e005600. [Google Scholar] [CrossRef]
  37. Ugowe, F.E.; Jackson, L.R., II; Thomas, K.L. Racial and ethnic differences in the prevalence, management, and outcomes in patients with atrial fibrillation: A systematic review. Heart Rhythm 2018, 15, 1337–1345. [Google Scholar] [CrossRef]
  38. Alhuneafat, L.; Jabri, A.; Poornima, I.G.; Alrifai, N.; Ali, M.; Elhamdani, A.; Kyvernitakis, A.; Al-Abdouh, A.; Mhanna, M.; Hadaddin, F.; et al. Ethnic and Racial Disparities in Resource Utilization and In-hospital Outcomes Among Those Admitted for Atrial Fibrillation: A National Analysis. Curr. Probl. Cardiol. 2022, 47, 101365. [Google Scholar] [CrossRef]
  39. Sainani, K.L. Propensity scores: Uses and limitations. PM&R 2012, 4, 693–697. [Google Scholar] [CrossRef]
  40. Khachatryan, T.; Hauschild, C.; Hoff, J.; Contractor, T.; Khachatryan, A.; Tran, H.; Matsuo, B.; Jacobson, A.; Hilliard, A. Review of Direct Oral Anticoagulants and Guide for Effective Drug Utilization. Am. J. Cardiovasc. Drugs 2019, 19, 525–539. [Google Scholar] [CrossRef]
  41. López-López, J.A.; Sterne, J.A.C.; Thom, H.H.Z.; Higgins, J.P.T.; Hingorani, A.D.; Okoli, G.N.; Davies, P.A.; Bodalia, P.N.; Bryden, P.A.; Welton, N.J.; et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: Systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 2017, 359, j5058. [Google Scholar] [CrossRef] [PubMed]
  42. Deitelzweig, S.; Bergrath, E.; di Fusco, M.; Kang, A.; Savone, M.; Cappelleri, J.C.; Russ, C.; Betts, M.; Cichewicz, A.; Schaible, K.; et al. Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: A systematic review and network meta-analysis. Future Cardiol. 2022, 18, 393–405. [Google Scholar] [CrossRef] [PubMed]
  43. Essien, U.R.; Chiswell, K.; Kaltenbach, L.A.; Wang, T.Y.; Fonarow, G.C.; Thomas, K.L.; Turakhia, M.P.; Benjamin, E.J.; Rodriguez, F.; Fang, M.C.; et al. Association of Race and Ethnicity with Oral Anticoagulation and Associated Outcomes in Patients with Atrial Fibrillation: Findings from the Get with the Guidelines-Atrial Fibrillation Registry. JAMA Cardiol. 2022, 7, 1207–1217. [Google Scholar] [CrossRef] [PubMed]
  44. Zhu, J.; Alexander, G.C.; Nazarian, S.; Segal, J.B.; Wu, A.W. Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010–2017. Pharmacotherapy 2018, 38, 907–920. [Google Scholar] [CrossRef]
  45. Sur, N.B.; Wang, K.; Di Tullio, M.R.; Gutierrez, C.M.; Dong, C.; Koch, S.; Gardener, H.; García-Rivera, E.J.; Zevallos, J.C.; Burgin, W.S.; et al. Disparities and Temporal Trends in the Use of Anticoagulation in Patients with Ischemic Stroke and Atrial Fibrillation. Stroke 2019, 50, 1452–1459. [Google Scholar] [CrossRef]
Jcm 14 03252 g001
Figure 1. Study design. Abbreviations: DOAC, direct oral anticoagulant; OAC, oral anti-coagulant.
Figure 1. Study design. Abbreviations: DOAC, direct oral anticoagulant; OAC, oral anti-coagulant.
Jcm 14 03252 g001
Jcm 14 03252 g002
Figure 2. Flow diagram of patients included in the study. Abbreviations: AF, atrial fibrillation; OAC, oral anti-coagulant.
Figure 2. Flow diagram of patients included in the study. Abbreviations: AF, atrial fibrillation; OAC, oral anti-coagulant.
Jcm 14 03252 g002
Table 1. Baseline demographic, socio-economic and clinical characteristics before IPTW weighting.
Table 1. Baseline demographic, socio-economic and clinical characteristics before IPTW weighting.
Warfarin Cohort (Reference)Apixaban CohortDabigatran CohortRivaroxaban Cohort
N/Mean%/SDN/Mean%/SDSTDN/Mean%/SDSTDN/Mean%/SDSTD
Sample Size278,372 486,257 46,920 267,991
Age78.157.5978.247.671.1976.677.2419.9776.997.3415.50
65–74100,17135.98%175,27536.05%0.1320,41043.50%15.40112,55142.00%12.35
75–84115,34441.44%199,40541.01%0.8718,77240.01%2.90108,35440.43%2.04
≥8562,85722.58%111,57722.95%0.87773816.49%15.4047,08617.57%12.53
Gender
Male137,78549.50%229,54947.21%4.5824,20651.59%4.19135,44250.54%2.09
Female140,58750.50%256,70852.79%4.5822,71448.41%4.19132,54949.46%2.09
Race
White247,64288.96%433,12789.07%0.3641,75088.98%0.07238,86189.13%0.54
Black16,2885.85%23,9054.92%4.1420494.37%6.7411,9714.47%6.26
Asian40941.47%85411.76%2.2710202.17%5.2652061.94%3.64
Other10,3483.72%20,6844.25%2.7421014.48%3.8411,9534.46%3.75
U.S. Geographic Region
Northeast52,50118.86%90,83918.68%0.46972920.74%4.70742250,05318.68%0.47
Midwest90,69532.58%111,18122.86%21.8310,59722.59%22.5052263,03923.52%20.26
South84,98330.53%199,40841.01%22.0017,91338.18%16.15975101,97138.05%15.90
West49,49817.78%83,43917.16%1.64855118.22%1.1540552,19119.47%4.35
Other6950.25%13900.29%0.701300.28%0.5346447370.28%0.50
Index Year
201370,65425.38%79751.64%74.0613,33028.41%6.8334,20512.76%32.54
201457,60020.69%32,3756.66%41.72877818.71%4.9944,96016.78%10.05
201546,69716.78%56,93811.71%14.53571512.18%13.0937,57914.02%7.63
201638,02113.66%78,29716.10%6.87810917.28%10.0336,57513.65%0.03
201729,50210.60%79,51416.35%16.91626913.36%8.5244,27016.52%17.36
201820,9037.51%111,52622.94%43.9732236.87%2.4838,30414.29%21.90
201914,9955.39%119,63224.60%55.8814963.19%10.8732,09811.98%23.57
Medicaid Dual Eligibility43,34515.57%67,72713.93%4.63650113.86%4.8438,73314.45%3.13
Part-D LIS58,49421.01%93,53719.24%4.43907419.34%4.1752,34019.53%3.69
SES Variable
Low119,23642.83%192,28939.54%6.6918,72639.91%5.94105,07639.21%7.37
Medium115,66241.55%194,91340.08%2.9818,74639.95%3.25106,73839.83%3.50
High43,47415.62%99,05520.37%12.40944820.14%11.8256,17720.96%13.86
Baseline Comorbidity
  CCI5.652.365.582.393.025.092.2124.555.182.2620.27
  CHA2DS2-VASc Score4.671.734.511.699.574.271.6923.794.251.6824.58
150771.82%90201.85%0.2313212.82%6.5972192.69%5.86
222,2327.99%45,9889.46%5.22552511.78%12.7232,26612.04%13.53
347,15216.94%89,60718.43%3.90992421.15%10.7456,24420.99%10.34
4+203,91173.25%341,64270.26%6.6530,15064.26%19.49172,26264.28%19.45
  HAS-BLED Score2.681.222.671.180.762.461.0918.662.491.1115.81
082522.96%13,4042.76%1.2513272.83%0.8181363.04%0.42
133,79312.14%52,77010.85%4.04593512.65%1.5533,19212.39%0.75
290,99532.69%167,86234.52%3.8819,36241.27%17.84105,86039.50%14.22
3+145,33252.21%252,22151.87%0.6820,29643.26%17.99120,80345.08%14.30
Bleeding history53,07019.06%83,55017.18%4.89734815.66%8.9942,63415.91%8.31
Obesity56,14820.17%124,13825.53%12.79950820.26%0.2361,32122.88%6.60
CHF94,70634.02%133,60327.48%14.2211,75025.04%19.7864,64824.12%21.93
DM108,00738.80%168,14634.58%8.7616,36634.88%8.1390,10233.62%10.79
Hypertension234,99684.42%413,63885.07%1.8039,55384.30%0.33224,97883.95%1.28
COPD84,22730.26%141,16529.03%2.6812,76427.20%6.7574,06527.64%5.78
Renal disease79,36928.51%128,56826.44%4.64803417.12%27.3951,34119.16%22.09
MI39,35914.14%56,43811.61%7.5743529.28%15.1726,0129.71%13.71
Dyspepsia55,54219.95%90,91518.70%3.18832617.75%5.6549,09618.32%4.15
Non-stroke/SE PVD74,76426.86%128,09826.34%1.1610,40322.17%10.9162,89523.47%7.81
History of stroke/SE43,18715.51%62,59312.87%7.58577912.32%9.2528,59510.67%14.40
TIA26,6719.58%54,83211.28%5.5542379.03%1.9023,0158.59%3.46
PAD72,57526.07%116,77224.01%4.75991421.13%11.6658,78921.94%9.69
CAD125,84045.21%202,79341.70%7.0719,26441.06%8.38106,08839.59%11.39
Baseline Medication Use
ACE/ARB127,79745.91%209,62043.11%5.6422,06047.02%2.22118,79444.33%3.18
Amiodarone15,3395.51%30,6646.31%3.3834377.33%7.4116,6366.21%2.97
Beta-blockers168,48160.52%299,31561.55%2.1129,39562.65%4.37161,76660.36%0.33
H2-RA19,6967.08%36,7007.55%1.8130966.60%1.8918,3426.84%0.91
Proton pump inhibitor81,77729.38%147,41830.32%2.0513,47028.71%1.4778,25529.20%0.39
Statins154,02855.33%284,80958.57%6.5526,65456.81%2.97152,14056.77%2.90
Anti-platelets40,20414.44%74,08815.24%2.23642913.70%2.1337,48113.99%1.31
NSAIDS51,42718.47%107,21922.05%8.9010,26021.87%8.4661,26722.86%10.85
Dose
Standard 316,47265.08% 37,76380.48% 177,98366.41%
Low 112,52223.14% 856618.26% 75,68428.24%
Unknown 57,26311.78% 5911.26% 14,3245.34%
Abbreviations: SD: standard deviation, STD: standardized mean difference (after multiplying by 100), LIS: low-income subsidy, SES: socio-economic status, CCI: Charlson comorbidity index, CHF: congestive heart failure, DM: diabetes mellitus, COPD: chronic obstructive pulmonary disease, MI: myocardial infarction, PVD: peripheral vascular disease, SE: systemic embolism, TIA: transient ischemic attack, PAD: peripheral arterial disease, CAD: coronary artery disease, ACE: angiotensin-converting enzyme, ARB: angiotensin receptor blockers, RA: receptor antagonist, NSAIDS: non-steroidal anti-inflammatory drug.
Table 2. Baseline demographic, socio-economic and clinical characteristics after IPTW weighting.
Table 2. Baseline demographic, socio-economic and clinical characteristics after IPTW weighting.
Warfarin (Reference)Apixaban CohortDabigatran CohortRivaroxaban Cohort
N/Mean%/SDN/Mean%/SDSTDN/Mean%/SDSTDN/Mean%/SDSTD
Sample Size278,372 486,257 46,920 267,991
Age77.687.6477.717.550.3377.977.593.7777.847.512.12
65–74108,51438.98%188,08938.68%0.6217,18336.62%4.8799,67737.19%3.68
75–84111,37540.01%197,11140.54%1.0719,56141.69%3.42112,52841.99%4.03
≥8558,48221.01%101,05820.78%0.5610,17621.69%1.6655,78620.82%0.47
Gender
Male143,02151.38%232,22347.76%7.2523,56650.23%2.31130,68148.76%5.23
Female135,35148.62%254,03452.24%7.2523,35449.77%2.31137,31051.24%5.23
Race
White248,43589.25%435,38389.54%0.9541,32088.07%3.72238,21188.89%1.15
Black15,8425.69%22,3924.61%4.9222904.88%3.6212,7184.75%4.25
Asian35811.29%86901.79%4.0711232.39%8.2452871.97%5.42
Other10,5143.78%19,7914.07%1.5121874.66%4.4011,7754.39%3.12
U.S. Geographic Region
Northeast50,90518.29%90,79618.67%0.99860718.34%0.1550,19318.73%1.14
Midwest73,09626.26%123,99625.50%1.7311,06923.59%6.1768,02225.38%2.00
South104,80537.65%182,46337.52%0.2618,45539.33%3.46100,49737.50%0.31
West48,82517.54%87,72118.04%1.31867718.49%2.4848,53518.11%1.49
Other7410.27%12800.26%0.051120.24%0.567440.28%0.22
Index Year
201332,67311.74%57,22111.77%0.09548911.70%0.1231,57211.78%0.14
201437,14113.34%64,93113.35%0.03619413.20%0.4235,80313.36%0.05
201538,01813.66%66,21413.62%0.12631513.46%0.5836,55413.64%0.05
201641,62514.95%72,50814.91%0.12697714.87%0.2439,81414.86%0.27
201741,04514.74%71,72114.75%0.01695114.81%0.2039,65114.80%0.14
201844,50815.99%78,12016.07%0.21762016.24%0.6942,99016.04%0.14
201943,36115.58%75,54215.54%0.11737415.72%0.3941,60615.53%0.14
Medicaid Dual Eligibility36,64113.16%67,63313.91%2.18673414.35%3.4541,27715.40%6.40
Part-D LIS50,39318.10%93,74419.28%3.02925519.72%4.1455,14820.58%6.27
SES Variable
Low111,79140.16%193,87739.87%0.5918,55539.55%1.25108,33040.42%0.54
Medium113,95040.93%197,74340.67%0.5518,76239.99%1.93108,14940.36%1.18
High52,63218.91%94,63719.46%1.41960320.47%3.9251,51219.22%0.80
Baseline Comorbidity
CCI5.502.385.442.342.715.492.350.705.452.342.40
CHA2DS2-VASc Score4.471.704.451.701.124.501.722.024.471.710.25
162162.2%10,1532.1%1.0010222.2%0.3755772.1%1.05
226,6559.58%49,17210.11%1.8045019.59%0.0626,7089.97%1.32
352,96719.03%92,96019.12%0.23869918.54%1.2550,43818.82%0.53
4+192,53469.16%333,97268.68%1.0432,69969.69%1.14185,26969.13%0.07
HAS-BLED Score2.621.222.611.150.332.641.171.612.611.150.32
092693.33%12,6412.60%4.3012332.63%4.1371992.69%3.77
136,17813.00%53,35210.97%6.24541211.53%4.4629,51911.02%6.10
293,05333.43%179,79436.98%7.4316,52635.22%3.7897,51236.39%6.21
3+139,87350.25%240,47049.45%1.5923,75050.62%0.74133,76149.91%0.67
Bleeding history53,65219.27%80,97816.65%6.83804117.14%5.5444,93216.77%6.53
Obesity63,90322.96%113,41723.32%0.8711,08923.63%1.6064,07123.91%2.25
CHF83,52730.01%133,07327.37%5.8412,82127.33%5.9371,95026.85%7.00
DM100,26836.02%167,98034.55%3.0816,97036.17%0.3196,23635.91%0.23
Hypertension231,26683.08%414,31585.20%5.8339,94685.14%5.63229,38285.59%6.92
COPD79,41728.53%139,57328.70%0.3913,11527.95%1.2877,13228.78%0.56
Renal disease69,10024.82%120,01524.68%0.3311,73925.02%0.4566,53024.83%0.01
MI36,54813.13%55,33311.38%5.34491410.47%8.2428,81910.75%7.33
Dyspepsia51,52918.51%92,37119.00%1.24851218.14%0.9650,90418.99%1.24
Non-stroke/SE PVD71,11125.55%122,59725.21%0.7712,06925.72%0.4169,83226.06%1.17
History of stroke/SE38,71513.91%60,19212.38%4.53677414.44%1.5232,17012.00%5.67
TIA27,6909.95%49,64710.21%0.87528611.27%4.2826,0339.71%0.78
PAD66,61423.93%114,10223.47%1.0911,27724.04%0.2565,43824.42%1.14
CAD118,33342.51%207,56142.69%0.3619,87742.36%0.29110,90241.38%2.28
Baseline Medication Use
ACE/ARB118,78542.67%219,10845.06%4.8221,40245.61%5.93120,24344.87%4.43
Amiodarone14,5255.22%34,0106.99%7.4232917.01%7.5017,0006.34%4.83
Beta-blockers164,70659.17%308,11563.36%8.6229,14462.11%6.03163,40060.97%3.69
H2-RA19,3076.94%35,5297.31%1.4434097.26%1.2819,4257.25%1.22
Proton pump inhibitor79,01728.39%148,68130.58%4.8113,64629.08%1.5480,30029.96%3.47
Statins153,55355.16%285,75858.77%7.2927,22258.02%5.77154,45457.63%4.99
Anti-platelets37,88413.61%76,18815.67%5.83684414.59%2.8140,19115.00%3.97
NSAIDS52,31118.79%106,89621.98%7.9310,15721.65%7.1160,85322.71%9.67
Dose
Standard 336,91569.29% 34,65473.86% 167,08262.35%
Low 113,08123.26% 943420.11% 82,55730.81%
Unknown 36,2617.46% 28326.04% 18,3526.85%
Abbreviations: SD: Standard deviation, STD: standardized mean difference (after multiplying by 100), LIS: low-income subsidy, SES: socioeconomic status, CCI: Charlson comorbidity index, CHF: congestive heart failure, DM: diabetes mellitus, COPD: chronic obstructive pulmonary disease, MI: myocardial infarction, PVD: peripheral vascular disease, SE: systemic embolism, TIA: transient ischemic attack, PAD: peripheral arterial disease, CAD: coronary artery disease, ACE: angiotensin-converting enzyme, ARB: angiotensin receptor blockers, RA: receptor antagonist, NSAIDS: non-steroidal anti-inflammatory drug.
Table 3. Risk of stroke (HR, 95% CI) overall and by subgroups.
Table 3. Risk of stroke (HR, 95% CI) overall and by subgroups.
Warfarin (Ref) vs. ApixabanApixaban vs. Dabigatran (Ref)Apixaban vs. Rivaroxaban (Ref)Warfarin (Ref) vs. DabigatranWarfarin (Ref) vs. RivaroxabanRivaroxaban (Ref) vs. Dabigatran
Overall
Stroke/SE0.69 (0.65,0.74)<0.00010.88 (0.80,0.95)0.00290.88 (0.84,0.92)<0.00010.82 (0.69,0.98)0.02540.77 (0.71,0.84)<0.00011.01 (0.92,1.10)0.8586
Ischemic stroke0.75 (0.69,0.81)<0.00010.82 (0.75,0.90)<0.00010.93 (0.88,0.97)0.00120.94 (0.78,1.13)0.50250.78 (0.71,0.86)<0.00011.14 (1.03,1.26)0.0102
Hemorrhagic stroke0.57 (0.49,0.67)<0.00011.41 (1.09,1.85)0.01040.76 (0.69,0.83)<0.00010.53 (0.32,0.86)0.01050.81 (0.67,0.98)0.03020.53 (0.41,0.70)<0.0001
SE0.40 (0.29,0.55)<0.00010.65 (0.43,0.98)0.04070.65 (0.52,0.79)<0.00010.27 (0.08,0.90)0.03340.48 (0.32,0.73)0.00050.98 (0.64,1.49)0.9203
65–74
Stroke/SE0.73 (0.67,0.78)<0.00010.92 (0.78,1.08)0.30170.87 (0.80,0.94)0.00040.79 (0.67,0.94)0.00670.83 (0.77,0.91)<0.00010.96 (0.81,1.13)0.6096
Ischemic stroke0.79 (0.72,0.87)<0.00010.83 (0.69,0.98)0.0330.90 (0.82,0.98)0.02160.97 (0.81,1.16)0.71290.88 (0.79,0.97)0.01031.10 (0.92,1.32)0.2911
Hemorrhagic stroke0.57 (0.48,0.67)<0.00011.68 (1.02,2.78)0.04190.82 (0.69,0.98)0.03120.33 (0.20,0.55)<0.00010.68 (0.57,0.82)<0.00010.50 (0.30,0.82)0.0068
SE0.57 (0.39,0.84)0.00420.97 (0.41,2.26)0.93930.60 (0.41,0.87)0.00650.60 (0.26,1.40)0.23680.96 (0.66,1.41)0.84400.62 (0.27,1.46)0.2752
75–84
Stroke/SE0.67 (0.64,0.72)<0.00010.92 (0.81,1.06)0.26070.88 (0.83,0.94)0.00010.73 (0.64,0.84)<0.00010.76 (0.72,0.82)<0.00010.96 (0.83,1.11)0.5840
Ischemic stroke0.75 (0.70,0.80)<0.00010.89 (0.76,1.03)0.12550.93 (0.87,1.00)0.06490.85 (0.73,1.00)0.04420.80 (0.74,0.87)<0.00011.06 (0.91,1.24)0.4435
Hemorrhagic stroke0.49 (0.43,0.55)<0.00011.57 (1.03,2.39)0.03560.77 (0.67,0.89)0.00030.31 (0.20,0.47)<0.00010.64 (0.55,0.74)<0.00010.48 (0.31,0.74)0.0008
SE0.50 (0.37,0.68)<0.00010.41 (0.24,0.70)0.00110.61 (0.44,0.83)0.00171.22 (0.71,2.07)0.47050.84 (0.62,1.15)0.27821.43 (0.83,2.45)0.1999
85+
Stroke/SE0.69 (0.66,0.72)<0.00010.84 (0.71,1.00)0.05170.90 (0.83,0.97)0.00740.82 (0.74,0.90)<0.00010.79 (0.75,0.83)<0.00011.07 (0.89,1.28)0.4666
Ischemic stroke0.76 (0.73,0.80)<0.00010.79 (0.66,0.96)0.01540.95 (0.87,1.04)0.27560.97 (0.87,1.08)0.55270.81 (0.77,0.86)<0.00011.21 (0.99,1.47)0.0611
Hemorrhagic stroke0.52 (0.48,0.57)<0.00011.09 (0.67,1.78)0.73640.71 (0.59,0.85)0.00020.36 (0.27,0.48)<0.00010.71 (0.64,0.79)<0.00010.65 (0.39,1.07)0.0872
SE0.49 (0.40,0.60)<0.00011.43 (0.43,4.78)0.55970.81 (0.53,1.24)0.33520.74 (0.48,1.15)0.18300.80 (0.65,1.00)0.04710.57 (0.17,1.94)0.3653
Male
Stroke/SE0.74 (0.69,0.78)<0.00010.80 (0.70,0.90)0.00030.91 (0.85,0.97)0.00300.93 (0.82,1.06)0.27520.81 (0.76,0.87)<0.00011.15 (1.02,1.31)0.0284
Ischemic stroke0.82 (0.77,0.88)<0.00010.70 (0.62,0.80)<0.00010.96 (0.89,1.04)0.32571.18 (1.03,1.36)0.01650.86 (0.79,0.93)0.00011.39 (1.21,1.59)<0.0001
Hemorrhagic stroke0.52 (0.46,0.58)<0.00011.92 (1.24,2.97)0.00340.73 (0.63,0.83)<0.00010.27 (0.17,0.41)<0.00010.71 (0.62,0.81)<0.00010.38 (0.25,0.59)<0.0001
SE0.69 (0.51,0.94)0.02010.66 (0.36,1.21)0.18300.99 (0.70,1.40)0.95371.03 (0.56,1.90)0.91380.70 (0.48,1.00)0.04841.50 (0.80,2.80)0.2100
Female
Stroke/SE0.73 (0.67,0.78)<0.00010.98 (0.86,1.11)0.73830.88 (0.83,0.93)<0.00010.79 (0.67,0.94)0.00670.83 (0.77,0.91)<0.00010.90 (0.79,1.02)0.0991
Ischemic stroke0.79 (0.72,0.87)<0.00010.97 (0.84,1.11)0.64990.92 (0.87,0.98)0.01210.97 (0.81,1.16)0.71290.88 (0.79,0.97)0.01030.96 (0.83,1.11)0.5818
Hemorrhagic stroke0.57 (0.48,0.67)<0.00011.14 (0.82,1.59)0.43980.80 (0.70,0.91)0.00060.33 (0.20,0.55)<0.00010.68 (0.57,0.82)<0.00010.69 (0.49,0.97)0.0302
SE0.57 (0.39,0.84)0.00420.68 (0.38,1.22)0.19970.51 (0.39,0.66)<0.00010.60 (0.26,1.40)0.23680.96 (0.66,1.41)0.84400.74 (0.41,1.32)0.3039
White
Stroke/SE0.69 (0.66,0.72)<0.00010.85 (0.77,0.93)0.00070.88 (0.84,0.92)<0.00010.82 (0.74,0.90)<0.00010.79 (0.75,0.83)<0.00011.04 (0.95,1.15)0.4239
Ischemic stroke0.76 (0.73,0.80)<0.00010.79 (0.71,0.88)<0.00010.94 (0.89,0.99)0.01860.97 (0.87,1.08)0.55270.81 (0.77,0.86)<0.00011.20 (1.08,1.33)0.0007
Hemorrhagic stroke0.52 (0.48,0.57)<0.00011.42 (1.07,1.89)0.01570.73 (0.66,0.81)<0.00010.36 (0.27,0.48)<0.00010.71 (0.64,0.79)<0.00010.51 (0.38,0.68)<0.0001
SE0.49 (0.40,0.60)<0.00010.65 (0.42,1.02)0.06140.61 (0.49,0.75)<0.00010.74 (0.48,1.15)0.18300.80 (0.65,1.00)0.04710.92 (0.59,1.44)0.7071
Black
Stroke/SE0.72 (0.63,0.83)<0.00011.41 (0.93,2.14)0.10500.90 (0.77,1.07)0.23140.52 (0.34,0.79)0.00220.81 (0.68,0.95)0.01090.65 (0.42,1.00)0.0475
Ischemic stroke0.78 (0.67,0.91)0.00131.68 (1.03,2.74)0.03900.93 (0.77,1.11)0.39250.47 (0.29,0.77)0.00280.85 (0.71,1.02)0.07820.56 (0.34,0.92)0.0232
Hemorrhagic stroke0.52 (0.36,0.75)0.00060.62 (0.26,1.44)0.26390.71 (0.45,1.11)0.12860.84 (0.36,1.95)0.68840.73 (0.47,1.12)0.14761.16 (0.49,2.79)0.7346
SE0.54 (0.27,1.06)0.07372.11 (0.14,31.25)0.58611.45 (0.52,4.00)0.47660.26 (0.02,3.70)0.31620.38 (0.14,1.02)0.05410.67 (0.04,10.84)0.7794
Asian
Stroke/SE0.58 (0.44,0.76)<0.00010.94 (0.55,1.60)0.81260.72 (0.56,0.93)0.01040.61 (0.35,1.05)0.07510.81 (0.61,1.08)0.14840.77 (0.45,1.32)0.3436
Ischemic stroke0.85 (0.61,1.20)0.36550.78 (0.45,1.35)0.37040.68 (0.52,0.90)0.00711.08 (0.60,1.95)0.80521.26 (0.89,1.79)0.19840.88 (0.51,1.54)0.6558
Hemorrhagic stroke0.30 (0.18,0.50)<0.00014.48 (0.36,55.56)0.24490.99 (0.53,1.86)0.98170.07 (0.01,0.82)0.03470.31 (0.17,0.56)0.00010.22 (0.02,2.82)0.2446
SE0.05 (0.01,0.45)0.007N/AN/A0.27 (0.02,3.17)0.2989N/AN/A0.17 (0.04,0.83)0.0281N/AN/A
Other
Stroke/SE0.84 (0.69,1.02)0.07320.95 (0.64,1.41)0.80020.97 (0.81,1.18)0.78420.89 (0.59,1.33)0.55960.85 (0.69,1.06)0.15881.03 (0.69,1.55)0.8737
Ischemic stroke0.81 (0.65,1.02)0.07720.93 (0.59,1.47)0.75640.88 (0.71,1.09)0.23280.89 (0.55,1.42)0.62080.91 (0.71,1.17)0.46940.97 (0.61,1.55)0.8993
Hemorrhagic stroke0.89 (0.59,1.35)0.58151.37 (0.51,3.66)0.53361.34 (0.87,2.07)0.18670.64 (0.23,1.77)0.38710.68 (0.41,1.12)0.13180.94 (0.34,2.63)0.9079
SE0.95 (0.38,2.38)0.91790.47 (0.13,1.70)0.25231.39 (0.54,3.60)0.50132.06 (0.51,8.34)0.31210.72 (0.24,2.17)0.55792.77 (0.67,11.54)0.1610
Low SES
Stroke/SE0.73 (0.69,0.77)<0.00011.00 (0.87,1.15)0.98330.88 (0.83,0.94)0.00010.73 (0.63,0.84)<0.00010.82 (0.77,0.88)<0.00010.89 (0.77,1.02)0.0994
Ischemic stroke0.81 (0.76,0.87)<0.00010.96 (0.83,1.12)0.62540.93 (0.86,1.00)0.04450.85 (0.73,0.99)0.03970.88 (0.81,0.95)0.00090.97 (0.83,1.14)0.7408
Hemorrhagic stroke0.52 (0.46,0.60)<0.00011.39 (0.93,2.07)0.10600.82 (0.71,0.96)0.01160.37 (0.25,0.55)<0.00010.63 (0.55,0.74)<0.00010.59 (0.39,0.89)0.0109
SE0.44 (0.33,0.60)<0.00010.68 (0.35,1.33)0.25710.46 (0.34,0.62)<0.00010.67 (0.34,1.29)0.22630.98 (0.74,1.31)0.89950.67 (0.34,1.30)0.2326
Medium SES
Stroke/SE0.67 (0.63,0.71)<0.00010.85 (0.73,0.98)0.02310.85 (0.79,0.91)<0.00010.80 (0.69,0.92)0.00230.79 (0.74,0.85)<0.00011.01 (0.87,1.17)0.9407
Ischemic stroke0.72 (0.67,0.78)<0.00010.79 (0.68,0.93)0.00440.89 (0.82,0.96)0.00370.92 (0.78,1.08)0.27980.81 (0.74,0.88)<0.00011.13 (0.96,1.33)0.1351
Hemorrhagic stroke0.55 (0.48,0.63)<0.00011.49 (0.96,2.34)0.07880.72 (0.62,0.83)<0.00010.36 (0.23,0.57)<0.00010.77 (0.66,0.89)0.00070.47 (0.30,0.74)0.0010
SE0.49 (0.36,0.66)<0.00010.49 (0.27,0.88)0.01810.74 (0.52,1.05)0.09520.98 (0.54,1.78)0.95470.66 (0.46,0.92)0.01581.51 (0.81,2.79)0.1930
High SES
Stroke/SE0.68 (0.62,0.74)<0.00010.73 (0.61,0.87)0.00060.95 (0.86,1.04)0.28020.92 (0.77,1.12)0.40690.71 (0.64,0.79)<0.00011.32 (1.09,1.59)0.0043
Ischemic stroke0.74 (0.67,0.83)<0.00010.65 (0.53,0.78)<0.00011.00 (0.90,1.12)0.92881.15 (0.93,1.41)0.18940.74 (0.65,0.84)<0.00011.57 (1.28,1.92)<0.0001
Hemorrhagic stroke0.50 (0.41,0.61)<0.00011.37 (0.78,2.44)0.27040.75 (0.61,0.91)0.00390.36 (0.21,0.65)0.00050.67 (0.54,0.83)0.00030.55 (0.31,0.97)0.0401
SE0.60 (0.38,0.93)0.02391.11 (0.38,3.23)0.84891.25 (0.75,2.08)0.38100.53 (0.18,1.57)0.24910.47 (0.27,0.81)0.00731.17 (0.38,3.40)0.7881
Dual
Stroke/SE0.80 (0.73,0.87)<0.00011.00 (0.82,1.22)0.96111.00 (0.91,1.10)0.96620.80 (0.65,0.98)0.03290.79 (0.72,0.88)<0.00011.01 (0.81,1.24)0.9648
Ischemic stroke0.92 (0.83,1.02)0.10311.06 (0.76,1.32)0.63331.03 (0.92,1.15)0.59000.97 (0.77,1.22)0.79890.88 (0.78,1.00)0.04541.10 (0.87,1.39)0.4120
Hemorrhagic stroke0.55 (0.45,0.67)<0.00010.59 (0.87,1.15)0.12061.05 (0.83,1.34)0.68200.32 (0.17,0.62)0.00070.52 (0.40,0.66)<0.00010.63 (0.32,1.23)0.1715
SE0.42 (0.28,0.64)<0.00011.44 (0.26,3.78)0.45490.52 (0.33,0.81)0.00400.62 (0.24,1.60)0.32090.83 (0.55,1.27)0.39290.73 (0.28,1.91)0.5210
Non Dual
Stroke/SE0.68 (0.65,0.71)<0.00010.87 (0.79,0.96)0.00470.85 (0.81,0.89)<0.00010.79 (0.71,0.87)<0.00010.81 (0.77,0.85)<0.00010.98 (0.89,1.09)0.7089
Ischemic stroke0.75 (0.71,0.78)<0.00010.81 (0.73,0.90)0.00010.90 (0.85,0.95)<0.00010.92 (0.83,1.03)0.14880.83 (0.79,0.88)<0.00011.11 (1.00,1.24)0.0558
Hemorrhagic stroke0.52 (0.47,0.57)<0.00011.40 (1.04,1.87)0.02470.71 (0.64,0.79)<0.00010.37 (0.28,0.49)<0.00010.73 (0.66,0.81)<0.00010.50 (0.38,0.68)<0.0001
SE0.52 (0.42,0.65)<0.00010.66 (0.41,1.04)0.07030.68 (0.54,0.86)0.00100.79 (0.50,1.25)0.31350.77 (0.61,0.97)0.02571.03 (0.65,1.65)0.8889
Abbreviations: HR: hazard ratio, CI: confidence interval, SE: systemic embolism, SES: socioeconomic status.
Table 4. Risk (HR, 95% CI)) of MB overall and by subgroups.
Table 4. Risk (HR, 95% CI)) of MB overall and by subgroups.
Apixaban vs. Warfarin (Ref)Apixaban vs. Dabigatran (Ref)Apixaban vs. Rivaroxaban (Ref)Dabigatran vs. Warfarin (Ref)Rivaroxaban vs. Warfarin (Ref)Dabigatran vs. Rivaroxaban (Ref)
Overall
MB0.59 (0.57,0.60)<0.00010.76 (0.72,0.80)<0.00010.60 (0.58,0.61)<0.00010.77 (0.73,0.81)<0.00010.99 (0.96,1.01)0.31810.78 (0.73,0.82)<0.0001
 GI bleeding0.61 (0.59,0.63)<0.00010.63 (0.59,0.67)<0.00010.52 (0.51,0.54)<0.00010.96 (0.90,1.03)0.23731.16 (1.12,1.19)<0.00010.83 (0.78,0.88)<0.0001
 Intracranial hemorrhage0.53 (0.51,0.56)<0.00011.19 (1.03,1.39)0.01870.86 (0.81,0.92)<0.00010.44 (0.38,0.52)<0.00010.62 (0.58,0.66)<0.00010.72 (0.62,0.84)<0.0001
Other bleeding0.59 (0.56,0.63)<0.00011.23 (1.02,1.47)0.02640.68 (0.63,0.72)<0.00010.48 (0.40,0.57)<0.00010.88 (0.82,0.94)0.00030.55 (0.46,0.66)<0.0001
65–74
MB0.57 (0.54,0.60)<0.00011.03 (0.92,1.15)0.63460.63 (0.60,0.66)<0.00010.55 (0.49,0.62)<0.00010.90 (0.86,0.95)<0.00010.61 (0.55,0.69)<0.0001
 GI bleeding0.58 (0.55,0.62)<0.00010.84 (0.74,0.96)0.00950.57 (0.54,0.60)<0.00010.69 (0.60,0.78)<0.00011.02 (0.96,1.09)0.45970.67 (0.59,0.76)<0.0001
 Intracranial hemorrhage0.53 (0.47,0.59)<0.00011.50 (1.09,2.07)0.01220.90 (0.79,1.01)0.07310.35 (0.25,0.48)<0.00010.59 (0.52,0.67)<0.00010.60 (0.43,0.83)0.0018
Other bleeding0.58 (0.52,0.66)<0.00012.11 (1.42,3.12)0.00020.70 (0.62,0.79)<0.00010.28 (0.19,0.41)<0.00010.83 (0.73,0.93)0.00250.34 (0.23,0.50)<0.0001
75–84
MB0.58 (0.56,0.60)<0.00010.77 (0.71,0.84)<0.00010.61 (0.58,0.63)<0.00010.75 (0.69,0.82)<0.00010.96 (0.93,1.00)0.05820.78 (0.71,0.85)<0.0001
 GI bleeding0.61 (0.58,0.64)<0.00010.65 (0.59,0.71)<0.00010.53 (0.51,0.56)<0.00010.94 (0.85,1.03)0.18681.14 (1.09,1.20)<0.00010.82 (0.74,0.90)<0.0001
 Intracranial hemorrhage0.51 (0.47,0.55)<0.00011.19 (0.95,1.49)0.13830.90 (0.82,0.99)0.02270.43 (0.34,0.54)<0.00010.57 (0.52,0.62)<0.00010.75 (0.60,0.95)0.0161
Other bleeding0.59 (0.54,0.65)<0.00011.17 (0.89,1.54)0.26240.68 (0.62,0.76)<0.00010.50 (0.38,0.66)<0.00010.87 (0.78,0.97)0.01000.58 (0.44,0.76)<0.0001
85+
MB0.63 (0.60,0.66)<0.00010.63 (0.56,0.70)<0.00010.56 (0.53,0.59)<0.00011.01 (0.90,1.12)0.88641.13 (1.08,1.19)<0.00010.89 (0.79,0.99)0.0302
 GI bleeding0.64 (0.61,0.68)<0.00010.50 (0.44,0.57)<0.00010.48 (0.45,0.51)<0.00011.28 (1.13,1.45)0.00011.34 (1.26,1.43)<0.00010.95 (0.84,1.08)0.4499
 Intracranial hemorrhage0.60 (0.54,0.65)<0.00011.10 (0.83,1.46)0.49340.81 (0.73,0.91)0.00020.54 (0.41,0.72)<0.00010.74 (0.66,0.82)<0.00010.73 (0.55,0.98)0.0357
Other bleeding0.65 (0.57,0.74)<0.00010.92 (0.65,1.31)0.65440.65 (0.57,0.75)<0.00010.69 (0.49,0.99)0.04270.99 (0.86,1.15)0.90190.70 (0.49,1.01)0.0537
Male
MB0.58 (0.56,0.60)<0.00010.82 (0.76,0.89)<0.00010.61 (0.59,0.63)<0.00010.70 (0.65,0.76)<0.00010.95 (0.92,0.99)0.0130.74 (0.68,0.80)<0.0001
 GI bleeding0.59 (0.56,0.62)<0.00010.67 (0.60,0.73)<0.00010.53 (0.50,0.55)<0.00010.88 (0.80,0.97)0.01031.12 (1.07,1.17)<0.00010.79 (0.71,0.87)<0.0001
 Intracranial hemorrhage0.54 (0.51,0.59)<0.00011.57 (1.25,2.00)0.00020.92 (0.84,1.00)0.05360.35 (0.27,0.44)<0.00010.59 (0.54,0.65)<0.00010.58 (0.46,0.74)<0.0001
Other bleeding0.60 (0.55,0.65)<0.00011.03 (0.82,1.29)0.82300.67 (0.61,0.74)<0.00010.58 (0.46,0.72)<0.00010.88 (0.80,0.97)0.01230.65 (0.52,0.82)0.0002
Female
MB0.60 (0.58,0.62)<0.00010.72 (0.66,0.77)<0.00010.59 (0.57,0.61)<0.00010.84 (0.77,0.90)<0.00011.03 (0.99,1.07)0.15360.81 (0.75,0.87)<0.0001
 GI bleeding0.62 (0.60,0.65)<0.00010.60 (0.55,0.65)<0.00010.52 (0.50,0.55)<0.00011.04 (0.95,1.13)0.43621.19 (1.14,1.25)<0.00010.86 (0.79,0.94)0.0011
 Intracranial hemorrhage0.54 (0.50,0.58)<0.00010.98 (0.81,1.19)0.84220.83 (0.76,0.90)<0.00010.54 (0.45,0.66)<0.00010.65 (0.60,0.71)<0.00010.83 (0.68,1.02)0.0758
Other bleeding0.61 (0.56,0.67)<0.00011.65 (1.21,2.25)0.00160.69 (0.62,0.76)<0.00010.37 (0.27,0.50)<0.00010.89 (0.80,0.99)0.03130.41 (0.30,0.57)<0.0001
White
MB0.60 (0.58,0.62)<0.00010.74 (0.70,0.79)<0.00010.59 (0.58,0.61)<0.00010.80 (0.75,0.85)<0.00011.02 (0.99,1.04)0.28560.79 (0.74,0.83)<0.0001
 GI bleeding0.62 (0.60,0.65)<0.00010.61 (0.57,0.66)<0.00010.52 (0.51,0.54)<0.00011.01 (0.95,1.09)0.72261.20 (1.16,1.24)<0.00010.84 (0.79,0.90)<0.0001
 Intracranial hemorrhage0.54 (0.51,0.57)<0.00011.20 (1.02,1.41)0.02500.85 (0.80,0.90)<0.00010.45 (0.38,0.52)<0.00010.63 (0.59,0.68)<0.00010.70 (0.60,0.83)<0.0001
Other bleeding0.60 (0.56,0.64)<0.00011.20 (0.99,1.45)0.05990.67 (0.63,0.72)<0.00010.49 (0.41,0.60)<0.00010.89 (0.83,0.96)0.00310.56 (0.46,0.67)<0.0001
Black
MB0.59 (0.54,0.65)<0.00010.88 (0.69,1.13)0.31200.56 (0.50,0.62)<0.00010.67 (0.53,0.86)0.00161.06 (0.96,1.18)0.25340.63 (0.49,0.81)0.0003
 GI bleeding0.61 (0.55,0.69)<0.00010.79 (0.60,1.05)0.10170.52 (0.46,0.58)<0.00010.77 (0.58,1.02)0.06331.18 (1.05,1.33)0.00550.65 (0.49,0.86)0.0024
 Intracranial hemorrhage0.50 (0.39,0.64)<0.00010.78 (0.41,1.45)0.42790.83 (0.60,1.13)0.23160.66 (0.35,1.22)0.18430.61 (0.45,0.82)0.00131.08 (0.56,2.07)0.8219
Other bleeding0.60 (0.46,0.78)0.00013.11 (0.91,10.53)0.06960.61 (0.46,0.82)0.00090.19 (0.06,0.65)0.00810.98 (0.73,1.30)0.85920.20 (0.06,0.67)0.0094
Asian
MB0.46 (0.38,0.56)<0.00010.73 (0.50,1.07)0.11120.77 (0.63,0.94)0.01070.64 (0.43,0.94)0.02210.61 (0.49,0.75)<0.00011.03 (0.70,1.52)0.8690
 GI bleeding0.37 (0.28,0.49)<0.00010.50 (0.31,0.81)0.00480.54 (0.41,0.72)<0.00010.75 (0.47,1.21)0.24190.68 (0.52,0.90)0.00651.08 (0.67,1.74)0.7517
 Intracranial hemorrhage0.55 (0.40,0.76)0.00031.33 (0.63,2.82)0.45941.36 (0.94,1.96)0.10160.42 (0.20,0.91)0.02820.41 (0.27,0.61)<0.00011.01 (0.46,2.22)0.9854
Other bleeding0.67 (0.34,1.32)0.25250.85 (0.25,2.89)0.79240.72 (0.40,1.32)0.29440.81 (0.22,2.89)0.73960.98 (0.49,1.99)0.95930.83 (0.24,2.88)0.7696
Other
MB0.56 (0.49,0.64)<0.00011.09 (0.79,1.51)0.58920.77 (0.67,0.88)0.00010.51 (0.37,0.71)<0.00010.74 (0.64,0.85)<0.00010.70 (0.50,0.97)0.0298
 GI bleeding0.50 (0.42,0.59)<0.00010.88 (0.60,1.28)0.50010.63 (0.54,0.75)<0.00010.57 (0.39,0.83)0.00360.79 (0.66,0.94)0.00730.72 (0.49,1.05)0.0890
 Intracranial hemorrhage0.64 (0.49,0.83)0.00071.77 (0.81,3.86)0.15141.12 (0.84,1.49)0.44740.36 (0.16,0.78)0.01020.58 (0.43,0.79)0.00060.61 (0.28,1.36)0.2303
Other bleeding0.85 (0.56,1.28)0.42361.58 (0.56,4.48)0.39221.06 (0.70,1.59)0.78170.54 (0.19,1.58)0.25980.79 (0.49,1.27)0.32730.69 (0.24,2.00)0.4908
Low SES
MB0.60 (0.57,0.62)<0.00010.76 (0.70,0.83)<0.00010.61 (0.59,0.63)<0.00010.78 (0.72,0.85)<0.00010.98 (0.94,1.02)0.32190.79 (0.73,0.87)<0.0001
 GI bleeding0.62 (0.59,0.65)<0.00010.65 (0.59,0.72)<0.00010.54 (0.52,0.57)<0.00010.94 (0.85,1.04)0.20651.14 (1.09,1.19)<0.00010.82 (0.75,0.91)<0.0001
 Intracranial hemorrhage0.53 (0.49,0.58)<0.00011.07 (0.86,1.34)0.55230.90 (0.81,0.99)0.03210.50 (0.40,0.62)<0.00010.59 (0.54,0.65)<0.00010.84 (0.67,1.06)0.1366
Other bleeding0.61 (0.55,0.67)<0.00011.23 (0.93,1.63)0.15360.70 (0.63,0.78)<0.00010.49 (0.37,0.64)<0.00010.87 (0.78,0.97)0.00970.56 (0.42,0.75)<0.0001
Medium SES
MB0.60 (0.58,0.63)<0.00010.77 (0.70,0.84)<0.00010.59 (0.56,0.61)<0.00010.78 (0.71,0.85)<0.00011.03 (0.99,1.07)0.17600.75 (0.68,0.82)<0.0001
 GI bleeding0.60 (0.57,0.64)<0.00010.62 (0.56,0.69)<0.00010.51 (0.48,0.53)<0.00010.97 (0.87,1.08)0.52051.19 (1.13,1.25)<0.00010.81 (0.73,0.90)<0.0001
 Intracranial hemorrhage0.56 (0.51,0.60)<0.00011.34 (1.04,1.73)0.02270.86 (0.78,0.95)0.00190.41 (0.32,0.53)<0.00010.65 (0.59,0.72)<0.00010.63 (0.49,0.82)0.0005
Other bleeding0.67 (0.61,0.75)<0.00011.17 (0.88,1.55)0.28890.68 (0.61,0.75)<0.00010.58 (0.43,0.77)0.00010.99 (0.89,1.11)0.89130.58 (0.44,0.78)0.0002
High SES
MB0.56 (0.52,0.59)<0.00010.75 (0.66,0.85)<0.00010.59 (0.55,0.62)<0.00010.75 (0.65,0.85)<0.00010.95 (0.89,1.02)0.14470.78 (0.69,0.89)0.0002
 GI bleeding0.62 (0.57,0.67)<0.00010.59 (0.51,0.68)<0.00010.52 (0.49,0.56)<0.00011.05 (0.90,1.22)0.55391.18 (1.09,1.29)<0.00010.88 (0.76,1.02)0.0929
 Intracranial hemorrhage0.50 (0.44,0.57)<0.00011.21 (0.87,1.68)0.24730.81 (0.71,0.92)0.00090.41 (0.30,0.57)<0.00010.62 (0.54,0.71)<0.00010.67 (0.48,0.93)0.0180
Other bleeding0.46 (0.39,0.53)<0.00011.45 (0.91,2.29)0.11540.61 (0.52,0.71)<0.00010.31 (0.20,0.50)<0.00010.75 (0.64,0.88)0.00050.42 (0.26,0.66)0.0002
Dual
MB0.59 (0.56,0.63)<0.00010.83 (0.72,0.95)0.00730.65 (0.61,0.69)<0.00010.72 (0.62,0.82)<0.00010.91 (0.86,0.97)0.00430.78 (0.68,0.90)0.0005
 GI bleeding0.57 (0.53,0.62)<0.00010.68 (0.58,0.80)<0.00010.56 (0.52,0.60)<0.00010.84 (0.72,0.98)0.02951.03 (0.96,1.11)0.44690.82 (0.70,0.95)0.0102
 Intracranial hemorrhage0.59 (0.51,0.67)<0.00011.19 (0.83,1.71)0.33961.07 (0.92,1.26)0.38230.49 (0.34,0.70)0.00010.55 (0.46,0.64)<0.00010.89 (0.62,1.30)0.5579
Other bleeding0.72 (0.61,0.84)<0.00011.80 (1.08,3.00)0.02470.82 (0.69,0.97)0.02420.40 (0.24,0.66)0.00040.88 (0.74,1.06)0.17950.45 (0.27,0.76)0.0026
Non Dual
MB0.59 (0.57,0.60)<0.00010.74 (0.69,0.79)<0.00010.58 (0.57,0.60)<0.00010.79 (0.74,0.84)<0.00011.01 (0.99,1.04)0.34780.78 (0.73,0.83)<0.0001
 GI bleeding0.61 (0.59,0.64)<0.00010.61 (0.57,0.65)<0.00010.51 (0.50,0.53)<0.00011.00 (0.94,1.08)0.91041.20 (1.16,1.24)<0.00010.84 (0.78,0.90)<0.0001
 Intracranial hemorrhage0.53 (0.50,0.56)<0.00011.22 (1.03,1.44)0.01950.83 (0.78,0.89)<0.00010.43 (0.37,0.51)<0.00010.64 (0.60,0.68)<0.00010.68 (0.57,0.80)<0.0001
Other bleeding0.58 (0.54,0.62)<0.00011.14 (0.94,1.38)0.19820.65 (0.60,0.70)<0.00010.50 (0.41,0.61)<0.00010.89 (0.83,0.97)0.00420.57 (0.46,0.69)<0.0001
Abbreviations: HR: hazard ratio, CI: confidence interval, SES: socioeconomic status.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Atreja, N.; Dubey, A.; Kohli, M.; Jiang, J.; Hagan, M.; Aweh, G.; Adams, S.; Cheng, D. Demographic and Socio-Economic Disparities in the Outcomes Among Patients with NVAF Treated with Oral Anticoagulants: A Real-World Evaluation of Medicare Beneficiaries. J. Clin. Med. 2025, 14, 3252. https://doi.org/10.3390/jcm14093252

AMA Style

Atreja N, Dubey A, Kohli M, Jiang J, Hagan M, Aweh G, Adams S, Cheng D. Demographic and Socio-Economic Disparities in the Outcomes Among Patients with NVAF Treated with Oral Anticoagulants: A Real-World Evaluation of Medicare Beneficiaries. Journal of Clinical Medicine. 2025; 14(9):3252. https://doi.org/10.3390/jcm14093252

Chicago/Turabian Style

Atreja, Nipun, Anandkumar Dubey, Monal Kohli, Jenny Jiang, Melissa Hagan, Gideon Aweh, Shayna Adams, and Dong Cheng. 2025. "Demographic and Socio-Economic Disparities in the Outcomes Among Patients with NVAF Treated with Oral Anticoagulants: A Real-World Evaluation of Medicare Beneficiaries" Journal of Clinical Medicine 14, no. 9: 3252. https://doi.org/10.3390/jcm14093252

APA Style

Atreja, N., Dubey, A., Kohli, M., Jiang, J., Hagan, M., Aweh, G., Adams, S., & Cheng, D. (2025). Demographic and Socio-Economic Disparities in the Outcomes Among Patients with NVAF Treated with Oral Anticoagulants: A Real-World Evaluation of Medicare Beneficiaries. Journal of Clinical Medicine, 14(9), 3252. https://doi.org/10.3390/jcm14093252

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop